Wednesday, June 7, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Phase I Clinical Trial Unit for Infectious Disease Therapeutics

by Global Biodefense Staff
December 18, 2014

The National Institute of Allergy and Infectious Diseases (NIAID) has announced new contract awards to support the Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases.

Since Phase I studies are often on the critical path for product development of bacterial, viral, parasitic, and fungal countermeasures, the ability to prepare protocols and execute trials in a timely manner is important.  To help meet these goals and move promising candidates into the clinical pipeline in a timely manner, DMID initially awarded contracts for the Phase I Unit in 2008.

The current contract announcement is the result of a recompete of these program requirements to continue to provide NIAID with the infrastructure necessary for the design and conduct of Phase I clinical trials for therapeutics.

Awards were made to the following organizations, with a maximum value of $90,000,000:

  • Dynport Vaccine Company
  • Duke University
  • Clinical Research Management

The types of trials conducted or planned include first-in-human small molecule and monoclonal antibody trials, corrected QT interval (QTc) trials, and drug-drug interaction trials.

The contracts were awarded via Solicitation Number: RFP-NIAID-DMID-NIHAI2013178

Tags: AwardsNIAID

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC